You are on page 1of 2

tors in ter ms of lower ing plasma cholesterol levels

by suppressing the hepatic production of ver y low
density
NHC

C
N
H
2
C
CH
2
H C
CH
2
H C
CH
2
O
lipoprotein (VLDL) and low densit y lipoprotein (LDL)
cholesterol
(1)
. A nu mber of methods have been devel-
F
oped for the analysis of this dr ug which include li!uid
ch romatography tandem mass spect romet r y
("- #)
$%L&
1'(
Journal of Food and Drug Analysis, Vol. 15, No. 2, 2007, Pages 139-1
藥物食品分析 第十五卷 第二期
Simultaneous Determination of Atorvastatin Calcium and
Ezetimibe in Pharmaceutical Formulations by Liquid
Chromatography
SYED SHANAZ QUTAB
1
, SYED NAEEM RAZZAQ
1
, ISLAM ULLAH
KHAN
2
*
, MUHAMMAD ASHFAQ
2
AND ZEBA AHMAD SHUJA
1
1.
!"#a$oo %a&ora'ories (P)'* %'d., 5 +.,. -d., %a#ore-5000, Pa.is'an
2.
De/ar'0en' of 1#e0is'ry, +o)ern0en' 1ollege 2ni)ersi'y, %a#ore-5000, Pa.is'an
()eceived* +ctober 1, "--,. Accepted* /ebruary " "--0)
ABSTRAcT
A simple precise and sensitive reverse-phase high perfor mance li!uid ch romatographic () %-$%L&) method has
been developed for t he !u a nt it at ion of ator va st at i n calciu m si mu lt a neou sly w it h e1et i m ibe i n pha r maceut
ical for mu lat ions. &hromatographic separation was achieved on a "2- 3 #., mm 24 $ypersil
5
phenyl-" column. 6luent was
monitored by absor- bance at "#" nm using a mi7ture of -.1 8 ammonium acetate (p$ ,.2) and acetonitrile in the ratio of
"9*0" (v:v). &alibration plots were linear in the concentration range of 1"-2" 4g mL
-1
for both atorvastatin calcium and
e1etimibe with correlation coef- ficient ()") between -.((,, and -.((('. ;he total run time is less than 2 min. ;he proposed
method was validated by testing its linearity recovery selectivity repeatability and L+D:L+< values and it was successfully
employed for the determination of atorvastatin calcium and e1etimibe in pharmaceutical tablet formulations.
=ey words* $%L& acetonitrile isocratic atorvastatin calcium e1etimibe
INTRODUcTION
At o r v a s t a t i n c a lc i u m ( /ig u r e 1) i s t h e
c a lc i u m salt ("*1) t r ihyd rate of >)-()?)?)@-"-(# -f
luorophenyl)- b d - d i h y d r o 7 y - 2 - ( 1 - m e t h y l e t
h y l ) - ' - p h e n y l -
#>( phenylamino)carbonyl@-l$-py r role-1-heptanoic
acid. At is a sy nthetic li!uid-reducing agent and an in
hibitor of ' - hyd r o7 y-' - m e t hylg lu t a r yl- c o e n 1
y m e A ( $ 8B -
liver thereby promoting the synthesis of LDL receptors
and the subse!uent reduction in serum LDL-&
(9-()
. /ew
$%L& methods for the determination of e1etimibe were
reported in literatures
(1--11)
. Although the combinational
use of atorvastatin and e1etimibe is continuously increas-
&oA) reduct ase. Ator vast at i n is t he most ef f icacious

of the cu r rently available $8B- &oA reductase in hibi-
CH
3
O
CH
3
CH OH OH O
Ca
2+
3H
2
O
with gradient elution
(2)
and isocratic $%L& methods for
the detection of the dr ug in biofluids
(, -0)
.
61etimibe (/igure ") a selective inhibitor of intes-
tinal cholesterol and related phy tosterol absor ption
is designated as 1-(#-fluorophenyl)-'())->'-(#-
fluorophenyl)-
' ( C ) - h y d r o 7 y p r o p y l @ - # ( C ) - (# - h y d r o 7 y p
h e n y l ) - " - a1etidinone. 61etimibe selectively prevents
the absorption
2
Figure 1 &hemical structure of atorvastatin calcium.
OH
OH
of cholesterol from dietary and biliary sources by blocD- ing the transport of cholesterol
through the intestinal wall.
F
; his reduces the overall deliver y of cholesterol to the
? Author for correspondence. ;el* E("-'''-#-#,0#-.
N
H
2
O
O
F
/a7* E("--#"-,'0,-92. 6-mail* iuDhanFgcu.edu.pD Figure 2 &hemical structure of e1etimibe.